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groups. Randomization was stratified at each treating site based on the reported paracetamol dose, perceived risk factors, and time to presentation. Adverse reactions and use of rescue drugs were documented throughout the treatment. A subset of patients had micro-RNA tested post hoc. Results: The incidence of vomiting, retching, or need for rescue antiemetic treatment within 2 h of NAC initiation was significantly lower for patients receiving the modified protocol (39/ 108; 36.1 %) versus the standard protocol (71/109; 65.1 %) (adjusted odds ratio (OR) 0.26; 97.5 % CI 0.13-0.52) as well as those who received ondansetron pretreatment (45/109; 41.3 %) compared with placebo (65/108; 60.2 %) (OR 0.41; 97.5 % CI 0.20-0.80). Decreased incidence of nausea, vomiting, or retching within 12 h of NAC initiation was also noted in the modified NAC group (OR 0.37; 97.5 % CI 0.18-0.79) and the ondansetron group (OR 0.35; . Patients with a greater than 50 % increase in alanine aminotransferase (ALT) from admission value did not differ between the standard and modified protocols although there was a higher proportion in the ondansetron-treated group (16/100; 16 %; OR 3.30; ). Severe anaphylactoid reactions that required drug treatment or that interrupted the NAC infusion were noted in five of 108 patients (4.6 %) in the modified protocol and 31 of 109 (28.4 %) in the standard protocol and were unaffected by ondansetron pretreatment. No difference was noted between standard and modified NAC protocols in micro-RNA analysis; however, the ondansetron-treated group had higher values than placebo-treated group. Conclusion: The 12-h, modified NAC dosing schedule resulted in less vomiting, fewer anaphylactoid reactions, and fewer treatment interruptions. Further research is needed to confirm the efficacy of the 12-h, modified acetylcysteine regimen and the adverse effects of ondansetron. Critique: Protocol amendments were made during the recruitment process, including a change in the paracetamol overdose treatment guidelines by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), decreasing the 4-h treatment threshold to 100 mcg/mL for all patients. Also, the study was underpowered to compare the modified versus the standard NAC protocol. Implications for Toxicologists: Ondansetron pretreatment in patients receiving IV NAC is effective in decreasing vomiting. However, it may lead to increased hepatic injury, as evidenced by both increased incidence of ALT elevation and elevated micro-RNA levels in the ondansetron group. The clinical significance of this is unknown, and further studies are required to assess if ondansetron use should be avoided in paracetamol poisoning. Before a shorter, modified IV NAC protocol can be considered as an alternative to the standard 20.25-21 h protocol, a controlled study should be performed. For comparison with the general, non-institutionalized population, standardized mortality ratios (SMR) were obtained from the Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (WONDER) database. For the analysis of risk factors, deaths for four outcomes were examined: all-cause, non-overdose, overdose, and opioid-related. The effect of each risk factor on the likelihood of death was explored in three periods of time following prison release: the first month, months 2 to 12, and subsequent months.
The main predictors measured were the effects of age, sex, race, whether the incarceration resulted from a violation of terms of the person's community supervision, length of incarceration, release type, and calendar year of release. Hazard ratios (HR) for death were calculated. Results: The study cohort included 76,208 prisoners with a total of 192,511 releases, with an all-cause mortality rate for released prisoners of 737 per 100,000 person-years. The leading cause of death in former prisoners was overdose (167 per 100,000 person-years), of which opioids were involved in 58.6 % (14.8 % of overall deaths). Specifically, pharmaceutical opioids were involved in 71 % of opioid deaths, 49 % of all overdose deaths, and 11 % of overall deaths. There was an increased mortality rate in the first week after release relative to subsequent weeks for overdoses but not for non-overdose deaths.
Interestingly, although women had a reduced risk for allcause death and non-overdose death, they were at greater risk for overdose death (HR 1.38) and opioid-related deaths (HR 1.39) than men.
Compared with a non-institutionalized population, the adjusted risk for all-cause death was 3.61-fold higher, and for overdose death, 10.33-fold higher among former prisoners. In all, former prisoners accounted for 8.3 % of all overdose deaths in the state of Washington from 2000 to 2009.
Additionally, incarceration due to violations of community supervision terms and release without community supervision were associated with an increased risk for all-cause death (HR 1.28 and HR 1.13, respectively). A small but significant reduction in the risk for all-cause and overdose death was seen with increasing lengths of incarceration. Conclusions: This study documents that former prisoners died at a higher rate than the general population, and that the leading cause of death was overdose. Opioids, particularly prescription opioids, were the drugs most often involved in these overdose deaths. Death among released prisoners primarily occurred early in the post-release period and affected women at a higher rate than men. Critique: The study used ICD-10 codes to identify the underlying cause of death, classifying a death as "substance-related" if any substance was listed among the multiple causes of death. This classification scheme is limited, since "opioidrelated deaths" included deaths for which opioids were combined with other substances. Other included deaths may have been unrelated to use of opioids. Implications for Toxicologist: The high proportion of death in the first week post-release suggests that enforced abstinence is associated with loss of tolerance and predictable effects on future mortality. Additionally, the finding that women leaving prison were at a higher risk of opioidrelated death than men may indicate the evolving demographic patterns of complications from opioid use. One possible intervention could include educating prisoners upon release about the risks of returning to opioid use with the pre-incarceration pattern. Background: Body packers are people who smuggle illicit drugs hidden in their gastrointestinal tract across international borders. Currently, the majority of packets identified by law enforcement are manufactured with a high degree of reproducibility and sophistication. Depending on the region of importation, cocaine and heroin are the drugs most commonly found in these packets. While an abdominal X-ray (AXR) has a reported sensitivity of 77 to 90 % in screening detainees for packets, it is unclear whether this modality can be used to demonstrate the clearance of all packets from the gastrointestinal tract. Assuring that no packets remain is important for patient safety and to prevent illicit drugs from entering the prison system. The difference between these two scenarios is related to the number of packets available for detection. Research Question: What is the sensitivity and specificity of AXR for the detection of residual cocaine packets in comparison to computed tomography (CT)? Methods: This was a prospective cohort study of consecutive, confirmed adult cocaine body packers who did not require surgery or intensive care unit admission and who gave informed consent for imaging studies. All patients underwent AXR and CT. CT images of the abdomen and pelvis were collected with a 16-slice device without contrast. AXR was performed with frontal views of the whole abdomen in supine position and a lateral pelvic view in the erect position. CT images were read by an onsite radiologist; AXR and CT images were read by two radiologists blinded to the clinical course. One radiologist was board-certified, the other was in training. Each radiologist recorded the presence or absence of packets, their number, size, and location. Results: A total of 412 patients were referred to the hospital by French customs as suspected or established body packers. AXR confirmed packets in 175 asymptomatic patients. Of these 175 subjects, eight ingested packets containing drugs other than cocaine and four others required surgery. Of the 163 eligible subjects, 25 were excluded because they did not have an AXR and CT, or the tests were completed more than 2 h apart. In the 138 subjects analyzed, 75 % were male, 74 % ingested machine-produced packets, and 94 % ingested packets containing solid cocaine; the average number of expelled packets was 66 (range, 38-86). CT performed after two packet-free stools revealed a single residual packet in 14 patients, confirmed by delayed expulsion or surgical removal. Seven of these 14 were in the stomach. The radiologists' reading of the AXR had a combined sensitivity of 32 %, specificity of 99 %, positive predictive value of 75 %, and negative predictive value of 93 %. Retained packets were missed in 10/14 (71 %) subjects by at least one radiologist using AXR. There were no packets that were missed on CT. There were no differences in the packets' form or patients in whom packets were missed on AXR. The effective radiation dose estimates for AXR and CT were 1.5 mSv and 11.3 mSv for men and 2.7 mSv and 13.4 mSv for women, respectively. Conclusion: CT should be utilized to ensure gastrointestinal tract clearance and safe discharge of cocaine body packers. Critique: This study is limited by the small number of radiologists who examined the AXR and CT studies. One radiologist was still in training, raising the question of their experience reading AXR for cocaine packets, and no kappa score was provided to determine agreement. Because only subjects who ingested cocaine packets were included, these findings may not be generalizable to packets of other substances. The authors do not state whether patients were observed after a negative CT for evidence of packet expulsion. Though rare, CT has also missed illicit drugs retained within the gastrointestinal tract.
Considering the subject population, it is important to ensure that informed consent was obtained without coercion. Implication for Toxicologists: AXR was unable to provide a sufficient negative predictive value to be of clinical usefulness in screening known cocaine body packers for the absence of remaining intestinal packets. Though case reports have described CT images missing a remaining packet, this remains the best practice. Given the large number of packets typically ingested, a screening AXR may be useful to confirm the diagnosis of body packing. However, it should not be used to rule out the presence of remaining packets, typically few in number, allowing discharge to the custody of legal authorities. CT remains the study of choice to establish the absence of remaining packets. As an aside, two packet-free bowel movements, a commonly used endpoint, does not appear sufficient to document complete bowel evacuation.
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Background: Though there is concern about systemic health effects of metal-on-metal hip replacements (MOMHR), little rigorous data exist. Cobalt and chromium are the primary metals released following implantation, especially in patients with poorly functioning prostheses. The chronic effects from these exposures, however, are unknown. To address this issue, the Food and Drug Administration has asked for crosssectional studies investigating effects up to 8 years after implantation and recommended monitoring of MOMHR patients for cardiovascular, neurological, renal, and thyroid abnormalities. Research Question: Is there a difference in systemic health effects between asymptomatic patients with a MOMHR and those without?
Methods: This cross-sectional cohort study of patients from a single surgeon compared subjects who had a MOMHR with controls who underwent a total hip arthroplasty using a nonmetal-on-metal prosthesis more than 5 years prior to recruitment. Study subjects were matched based on age, gender, and time since procedure. Blood, plasma, and urine were collected during a single research visit using appropriate collection techniques. The analysis was performed by two independent laboratories, and the mean value for each test was reported. All subjects underwent a battery of tests including: blood analyses of kidney, liver, thyroid, and hypothalamuspituitary axis (HPA) function; coagulation parameters; fasting lipids; iron and protein concentrations; trans-thoracic echocardiography (TTE); electrocardiography; and MRI of the liver, spleen, and pituitary glands. Testing for total bone mineral density, IQ, anxiety, and depression were also performed. Results: Thirty-five pairs of subjects were matched for age, gender, and time since surgery (average of approximately 8 years); one subject had a MOMHR and one had a non-MOMHR. Subjects in the MOMHR group had concentrations of cobalt and chromium 5-to 50-fold greater than their cohorts. Total body and upper extremity bone mineral density was 5 and 4 % higher in the MOMHR group, respectively, which achieved statistical significance. Other significant findings included TTE revealing 7.7 % lower EF and 6 % larger left ventricular end-diastolic diameter in the MOMHR group. There was no significant difference in the New York Heart Association cardiac failure, blood analyses of organ function or neuropsychological testing between groups. In the MOMHR group, the fractional excretions of cobalt and chromium, relative to creatinine, were 5 and 1 %, respectively. The excretion of cobalt and chromium did not relate to plasma metal concentrations. MRI suggested evidence of metal deposition in the livers and spleens of those in the MOMHR group. Conclusion: In asymptomatic subjects, MOMHR is associated with differences in cardiovascular and musculoskeletal testing 8 years after surgery compared to those who underwent conventional hip replacements. Critique: The study only included asymptomatic patients. Those with more significant effects from their MOMHR may have been excluded allowing selection bias, and this would benefit the findings on MOMHR safety. Subjects' pre-procedure data is limited to normal pre-operative care and does not allow comparison to the extensive testing performed in this analysis or assessment of baseline function. Though extensive testing was performed, the findings in this comparison are limited by what the authors had the foresight and ability to evaluate in this one-time evaluation. Additionally, the number of matched pairs is relatively small raising the possibility of a type II error for the parameters where no significant difference was noted. Finally, the absolute differences in the bone mineral density and ejection fraction noted between the two groups were smaller than the 95 % confidence intervals surrounding the mean values. The significance of these differences is therefore uncertain. Implication for Toxicologists: Patients with a MOMHR have elevated circulating cobalt and chromium concentrations. Although the long-term health effects of these elevations following MOMHR are unknown, these two metals can have important toxicologic effects following other exposures. This analysis reveals subtle differences in the musculoskeletal and cardiovascular systems of subjects who received a MOMHR. While there were no functional limitations from the observed differences in cardiac parameters, the presence of the abnormality suggests there is the potential for worse effects. From this data, there is no reason to recommend removal of metal-on-metal hip prostheses in the asymptomatic patient, but the cardiovascular function of these patients should be monitored and further study is needed to determine the strength of the association and whether the effects worsen over time.
